{"id":744029,"date":"2023-03-30T16:04:19","date_gmt":"2023-03-30T20:04:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial-results\/"},"modified":"2023-03-30T16:04:19","modified_gmt":"2023-03-30T20:04:19","slug":"biora-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biora-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2022-financial-results\/","title":{"rendered":"Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results"},"content":{"rendered":"
\n

\n Biora initiating preclinical testing with pharma collaborator\u2019s molecule following recent data exceeding the company\u2019s target bioavailability levels for systemic therapeutics platform<\/em>
\n \n <\/p>\n

\n No adverse events indicated in 14-day tox study for targeted therapeutics program<\/em>\n <\/p>\n

\n Announcing new brand names for Biora\u2019s therapeutics platforms: the NaviCap\u2122 targeted oral delivery platform and the BioJet\u2122 systemic oral delivery platform<\/em>\n <\/p>\n

\n Management will host conference call and webcast today at 4:30 PM Eastern \/ 1:30 PM Pacific<\/em>\n <\/p>\n

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and\u00a0reported financial results for the fourth quarter and full year ended December\u00a031, 2022.<\/p>\n

Today, the company launched new brand names for its two therapeutics platforms. Its targeted therapeutics platform, previously called the Drug Delivery System (DDS), will now be known as the NaviCap\u2122 targeted oral delivery platform<\/a>. The NaviCap capsule uses autolocation technology to navigate through the GI tract and deliver drug to a targeted location.<\/p>\n

Biora\u2019s systemic therapeutics platform, previously called the Oral Biotherapeutic Delivery System (OBDS), is now the BioJet\u2122 systemic oral delivery platform<\/a>. The BioJet device uses liquid jet injection to deliver biotherapeutics into the small intestine for uptake into systemic circulation. Biora is also taking this opportunity to update its program numbers, replacing PGN with BT, for Biora Therapeutics. A guide to the new platform names and program numbers is available in the Investor Q&A on Biora\u2019s website<\/a>.<\/p>\n

Biora recently completed execution of its 14-day toxicology study for its BT-600 program (formerly PGN-600). All planned doses were administered, and the company observed no adverse events or safety signals. The company is completing data analysis and reporting for the study, including analysis of device performance data for the over 600 devices administered during the study.<\/p>\n

Biora also recently shared topline results from preclinical studies with two drugs using its BioJet systemic oral delivery platform, in which it achieved more than double its target bioavailability of 15% using an endoscopically placed and activated next-gen device. The company observed an average bioavailability of 37% with semaglutide, a GLP-1 receptor agonist, and an average bioavailability of 51% with adalimumab, a monoclonal antibody. These results significantly exceeded the 15% bioavailability target set by Biora and its pharma collaborators for progression of further development and testing using the platform.<\/p>\n

“We are extremely pleased with our recent progress in development of our next-generation BioJet systemic delivery device. The excellent bioavailability results that we observed have enabled us to move forward with preclinical studies with one of our collaborator\u2019s molecules, and we are on track for our goal to progress our other collaborations and potential partnerships this year,\u201d said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. \u201cFor the NaviCap targeted delivery platform, we achieved an important milestone with the administration of over 600 devices during our 14-day toxicology study for BT-600, which is far more devices than we would expect to administer as part of a phase 1 study. We have some additional work to do to analyze the device performance as part of this animal study, and we look forward to sharing that data with the FDA as we move toward filing our IND for BT-600 later this year,\u201d continued Adi Mohanty.<\/p>\n

\n Fourth Quarter and Full Year 2022 and Other Recent Corporate Highlights<\/strong>\n <\/p>\n